Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 268

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 268
---
ayman) LLP. In connection with this offering, Winston & Strawn LLP is acting as counsel to the underwriters. Experts The financial statements of Drugs Made In America Acquisition Corp. as of June 30, 2024 and for the period from May 23, 2024 (inception) through June 30, 2024 appearing in this prospectus have been audited by MaloneBailey, LLP, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere in this prospectus, and are included in reliance on such report given on the authority of such firm as experts in auditing and accounting. Where you can find additional information We have filed with the SEC a registration statement on Form S -1under the Securities Act with respect to the securities we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information about us and our securities, you should refer to the registration statement of which this prospectus forms a part and the exhibits and schedules filed with the registration statement. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are materially complete but may not include a description of all aspects of such contracts, agreements or other documents, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. Upon completion of this offering, we will be subject to the information requirements of the Exchange Act and will file annual, quarterly and current event reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC’s website at www.sec.gov. 168

INDEX TO FINANCIAL STATEMENTS

| Financial Statements of Drugs Made In America Acquisition Corp.:                                                                                                                                                    
 Report of Independent Registered Public Accounting Firm (PCAOB ID: 206)                                                                                                                                             
 Balance Sheets as of September 30, 2024 (Unaudited) and June 30, 2024 (Audited)                                                                                                                                     
 Statements of Operations for the Period from May 23, 2024 (inception) through September 30, 2024 (Unaudited) and for the Period from May 23, 2024 (inception) through June 30, 2024 (Audited)                       |     | Page 
 F-2  
 F-3  
 F-4  |
|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-----|
| Statements